LONDON, March 11, 2025 (GLOBE NEWSWIRE) -- Kaerus Bioscience (www.kaerusbio.com), a clinical-stage biopharmaceutical company created by Medicxi for the development...
NEW YORK, March 6, 2025 /PRNewswire/ -- Baruch College ("Baruch"), a public college in New York City, is providing notice of...
Nashville, TN-based NonProfit Focused on Improving Systems Through Safety Science and Evidence-Based Approaches NASHVILLE, Tenn., March 6, 2025 /PRNewswire/ -- The...
Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N.J., March 6,...
WELLESLEY, Mass., March 5, 2025 /PRNewswire/ -- Sun Life U.S., a leading provider of employee benefits and human resource technology solutions,...
She will replace President and CEO Marian Baldini who will be retiring in December BLUE BELL, Pa., March 3, 2025...
Nes-Ziona, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
NKGen explores the use of troculeucel as a potential treatment option for post-stroke patients.SANTA ANA, Calif., March 03, 2025 (GLOBE...
BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
NEW ROCHELLE, N.Y., Feb. 27, 2025 /PRNewswire/ -- A new article in Autism and Adulthood presents guidelines for designing consent materials...
– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase...
--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint...
Ottawa, Ontario--(Newsfile Corp. - February 12, 2025) - More than half of Canadians lack a comprehensive retirement plan, and of...
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses...
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim...
– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly...
– New blinded preliminary BRTX-100 data described this past Saturday at prestigious “2025 Winners in Industry Innovations in MSK Health”...
ROSEMONT, Ill., Feb. 7, 2025 /PRNewswire/ -- Nicolas S. Piuzzi, MD, was recognized as the 2025 Kappa Delta Young Investigator Award...
MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...